Banning Spread Pricing on PBMs Alone May Have Little Impact, Study Suggests
Executive Summary
As legislation moves forward in Congress, an examination of high-utilization Part D-covered generic drugs concludes that other payers in the supply chain make almost as much money from spread pricing as PBMs do.